FINWIRES · TerminalLIVE
FINWIRES

SHA:600380

5 stories mentioning SHA:600380Updated 20d ago

Every FINWIRES story that references SHA:600380, newest first.

Asia

Joincare Pharmaceutical's Unit Gets Nod for Banxia Baizhu Tianma Granules

Joincare Pharmaceutical's (SHA:600380) indirectly-owned unit, Sichuan Guangda Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for Banxia Baizhu Tianma Decoction Granules, according to a Shanghai bourse filing on Friday.The drug is used to treat phlegm, strengthen the spleen, and eliminate dampness.The certificate is valid until July 20, 2031.The pharmaceutical company's shares fell 3% at the close.

SHA:600380
Asia

Joincare Pharmaceutical Gets China Regulatory Acceptance for Ankylosing Spondylitis Drug Application

Joincare Pharmaceutical (SHA:600380) said China's drug regulator accepted the market authorization application for laichangqita monoclonal antibody injection, according to a Tuesday filing with the Shanghai bourse.The drug, jointly developed by subsidiary Livzon Monoclonal and Beijing Xinkanghe, is used for treating ankylosing spondylitis.This marked the drug's second accepted indication after psoriasis.Shares of the pharmaceutical company were down 1% in recent trade.

SHA:600380
Asia

Joincare Pharmaceutical Extends Employee Stock Ownership Plan

Joincare Pharmaceutical (SHA:600380) extended its second-phase business partner stock ownership plan by 12 months to June 7, 2027.The plan holds 6.3 million shares, or 0.33% of the pharmaceutical company's total share capital, according to a Tuesday filing with the Shanghai bourse.Shares of Joincare Pharmaceutical were down 1% in recent trade.

SHA:600380
Asia

Joincare Pharmaceutical Gets Nod for JKN2501 for Injection's Clinical Trials

Joincare Pharmaceutical (SHA:600380) received approval from China's National Medical Products Administration for the clinical trials of JKN2501 for injection, according to a Shanghai bourse disclosure on Thursday.The drug, which inhibits bacterial β-lactamases, can be applied as a treatment for severe pneumonia, complicated urinary tract infections and other high-incidence infections.The drug, in combination with meropenem, is currently undergoing phase I clinical trials as a treatment for urinary tract infections.The pharmaceutical company invested 14.7 million yuan for the research and development of the drug.

SHA:600380
Asia

Joincare Pharmaceutical Q1 Profit Down 5%, Revenue Declines 9%

Joincare Pharmaceutical (SHA:600380) posted first-quarter attributable net profit of 415.0 million yuan, down 4.8% from 435.8 million yuan the previous year.Earnings per share remained at 0.23 yuan, according to a weekend filing on the Shanghai bourse.Operating revenue declined 9.0% year over year to 3.72 billion yuan from 4.09 billion yuan.

SHA:600380

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:600380 in your portfolio
WheelAI
WheelAI
Analyze SHA:600380 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:600380